Call Us + 33 1 84 88 31 00

Article R5121-198 of the French Public Health Code

The regional pharmacovigilance centres inform the Agence nationale de sécurité du médicament et des produits de santé on the same day of the reports of adverse reactions likely to be due to a blood-derived medicinal product that they have received.

Original in French 🇫🇷
Article R5121-198

Les centres régionaux de pharmacovigilance informent le jour même l’Agence nationale de sécurité du médicament et des produits de santé des déclarations d’effets indésirables susceptibles d’être dus à un médicament dérivé du sang qu’ils ont reçues.

Need help with this article? Get help from a French lawyer

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call us at +33 (0) 1 84 88 31 00 or send us an email.

Useful links

You have a question in French Business Law?

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call +33 (0) 1 84 88 31 00 or send us an email.

All information exchanged through this website will be communicated to lawyers registered with a French Bar and will remain confidential.